Physician profile
M Gareth Eck
NPI 1205892213
$1,974.29
in general payments reported to CMS, 2019-2025
36 companies · $44.16 in 2025
The $44.16 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $76.82 · 2021: $195 · 2022: $350 · 2023: $509 · 2024: $515 · 2025: $44.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $161.87 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $160.60 | 2019-2024 | Keytruda, Lynparza |
| Amgen INC. | $148.13 | 2019-2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $134.96 | 2022-2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.74 | 2019-2024 | Gilotrif |
| Jazz Pharmaceuticals INC. | $108.45 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.61 | 2020-2024 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $91.23 | 2021-2024 | Verzenio, Retevmo |
| G1 Therapeutics, INC. | $79.54 | 2022-2023 | Cosela |
| Novartis Pharmaceuticals Corporation | $75.64 | 2021-2023 | |
| Daiichi Sankyo INC. | $68.88 | 2024 | Enhertu |
| Pacira Pharmaceuticals Incorporated | $60.55 | 2019-2023 | Exparel |
| Acell, INC. | $53.59 | 2019 | |
| Davol INC. | $51.63 | 2022 | |
| Genzyme Corporation | $45.80 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $41.13 | 2024 | Imfinzi |
| Csl Behring | $38.54 | 2019-2020 | |
| Blueprint Medicines Corporation | $36.10 | 2020-2021 | |
| Ethicon US, LLC | $35.27 | 2019 | |
| Covidien Lp | $35.21 | 2019 | |
| Genentech USA, INC. | $34.89 | 2024 | Tecentriq, Alecensa |
| Seagen INC. | $28.28 | 2022-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $26.56 | 2019-2021 | |
| Polynovo North America LLC | $26.36 | 2023 | |
| Kci USA, INC. | $24.53 | 2020 | |
| Emd Serono, INC. | $22.13 | 2023 | Tepmetko |
| Janssen Biotech, INC. | $21.18 | 2024 | Rybrevant |
| Avanos Medical | $20.83 | 2024 | Peg |
| Medtronic, INC. | $20.36 | 2024 | Ligasure |
| Philips North America LLC | $19.09 | 2024 | (792) Multi Modality Ivus Other Systems |
| Teleflex LLC | $18.00 | 2023 | Quikclot |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2023 | Seglentis |
| Aveo Pharmaceuticals, INC. | $15.53 | 2021 | |
| Mylan Institutional INC. | $13.42 | 2022 | |
| Atricure, INC. | $13.13 | 2023 | |
| Karyopharm Therapeutics INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Eck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.